BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...He also serves as CSO of CNS play Syndesi Therapeutics S.A....
BioCentury | Mar 29, 2018
Emerging Company Profile

Strengthening synapses

...and fairly specific event in AD, which is one of the reasons for targeting ACh,” Syndesi...
...synapses, he added, the company’s modulators could improve synaptic transmission regardless of dependence on ACh. Syndesi...
...in Syndesi; details of the licensing agreement for the SV2A modulators are undisclosed. COMPANY PROFILE Syndesi Therapeutics S.A....
BioCentury | Mar 1, 2018
Company News

Management tracks: Alkermes, Helsinn

...general manager of U.S. Oncology at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Neurology company Syndesi Therapeutics S.A....
BioCentury | Feb 2, 2018
Financial News

UCB spinout Syndesi raises €17M series A

...UCB S.A. (Euronext:UCB) spinout Syndesi Therapeutics S.A. (Louvain-la-Neuve, Belgium) launched with a €17 million ($21.1 million) series A...
...granted the company exclusive, worldwide rights to a platform of synaptic vesicle protein (SV2A) modulators. Syndesi...
...proof of concept to treat cognitive impairment in patients with Alzheimer’s disease. Syndesi Therapeutics S.A., Louvain-la-Neuve, Belgium Alicia Parker Syndesi...
Items per page:
1 - 4 of 4
BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

...He also serves as CSO of CNS play Syndesi Therapeutics S.A....
BioCentury | Mar 29, 2018
Emerging Company Profile

Strengthening synapses

...and fairly specific event in AD, which is one of the reasons for targeting ACh,” Syndesi...
...synapses, he added, the company’s modulators could improve synaptic transmission regardless of dependence on ACh. Syndesi...
...in Syndesi; details of the licensing agreement for the SV2A modulators are undisclosed. COMPANY PROFILE Syndesi Therapeutics S.A....
BioCentury | Mar 1, 2018
Company News

Management tracks: Alkermes, Helsinn

...general manager of U.S. Oncology at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Neurology company Syndesi Therapeutics S.A....
BioCentury | Feb 2, 2018
Financial News

UCB spinout Syndesi raises €17M series A

...UCB S.A. (Euronext:UCB) spinout Syndesi Therapeutics S.A. (Louvain-la-Neuve, Belgium) launched with a €17 million ($21.1 million) series A...
...granted the company exclusive, worldwide rights to a platform of synaptic vesicle protein (SV2A) modulators. Syndesi...
...proof of concept to treat cognitive impairment in patients with Alzheimer’s disease. Syndesi Therapeutics S.A., Louvain-la-Neuve, Belgium Alicia Parker Syndesi...
Items per page:
1 - 4 of 4